{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:41:09Z","timestamp":1792449669470,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903472"],"award-info":[{"award-number":["81903472"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejmech.2025.117492","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T01:34:21Z","timestamp":1741484061000},"page":"117492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors"],"prefix":"10.1016","volume":"289","author":[{"given":"Shengfei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youli","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue'e","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianta","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weike","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117492_bib1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117492_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27089","article-title":"Acute myelogenous leukemia in adolescents and young adults","volume":"65","author":"Creutzig","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117492_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc989","article-title":"Disruption of differentiation in human cancer: AML shows the way","volume":"3","author":"Tenen","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117492_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2401568","article-title":"Treatment of relapsed and refractory acute myelogenous leukemia","volume":"14","author":"Estey","year":"2000","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117492_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM198008283030901","article-title":"Treatment of acute myelogenous leukemia in children and adults","volume":"303","author":"Weinstein","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117492_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117492_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2011-01-329532","article-title":"Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex","volume":"118","author":"Verstraete","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117492_bib8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ejmech.2025.117492_bib9","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117492_bib10","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117492_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117492_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117492_bib13","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/fon.14.105","article-title":"Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia","volume":"10","author":"Levis","year":"2014","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117492_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117492_bib15","doi-asserted-by":"crossref","first-page":"12403","DOI":"10.1021\/acs.jmedchem.0c00696","article-title":"Small-molecule Fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia","volume":"63","author":"Zhong","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117492_bib16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/joim.13738","article-title":"Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory\/relapsed acute myeloid leukemia with FLT3-ITD: a multicenter phase 2 study","volume":"295","author":"Yu","year":"2024","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117492_bib17","first-page":"69","article-title":"Gilteritinib improves outcomes in AML","volume":"17","author":"Sidaway","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ejmech.2025.117492_bib18","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ejmech.2025.117492_bib19","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117492_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bjh.13353","article-title":"A phase I\/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukemia and activating FLT3 mutations","volume":"169","author":"Fiedler","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2025.117492_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102221","article-title":"Cabozantinib: an evolving therapy for hepatocellular carcinoma","volume":"98","author":"El-Khoueiry I","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117492_bib22","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","article-title":"Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence","volume":"18","author":"Bergerot","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117492_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-017-0444-6","article-title":"Cabozantinib for renal cell carcinoma: current and future paradigms","volume":"18","author":"Abdelaziz","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117492_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2016.04.004","article-title":"Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)","volume":"376","author":"Lu","year":"2016","journal-title":"Cancer Lett."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117492_bib25","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1182\/blood.V128.22.5218.5218","article-title":"A phase I study of the multi-targeted tyrosine kinase inhibitor cabozantinib in patients with acute myeloid leukemia","volume":"128","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117492_bib26","first-page":"1","article-title":"Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy","volume":"3","author":"Warkentin","year":"2014","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117492_bib27","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/acs.jmedchem.1c01792","article-title":"Identification of 2-aminopyrimidine derivatives as FLT3 kinase inhibitors with high selectivity over c-KIT","volume":"65","author":"Tong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117492_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1196\/annals.1392.020","article-title":"Effect of FLT3 inhibition on normal hematopoietic progenitor cells","volume":"1106","author":"Weisel","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117492_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acs.jmedchem.8b01594","article-title":"Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117492_bib30","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.bmc.2013.06.026","article-title":"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors","volume":"21","author":"Qi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117492_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126630","article-title":"Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"29","author":"Xu","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117492_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ejmech.2014.06.068","article-title":"Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents","volume":"83","author":"Zhou","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117492_bib33","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2174\/092986707782023622","article-title":"Antiangiogenic agents: an update on small molecule VEGFR inhibitors","volume":"14","author":"Schenone","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117492_bib34","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/jm301537p","volume":"56","author":"Yang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117492_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112309","article-title":"Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3K\u03b1 inhibitors with potent antitumor activity","volume":"197","author":"Liao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117492_bib36","article-title":"Discovery of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"283","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117492_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ddtec.2015.10.007","article-title":"Protein kinase profiling assays: a technology review","volume":"18","author":"Wang","year":"2015","journal-title":"Drug Discov. Today Technol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117492_bib38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117492_bib39","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"Thomas, PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Daniel","year":"2013","journal-title":"J. Chem. Theor. Comput."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:13:09Z","timestamp":1762265589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425002570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":39,"alternative-id":["S0223523425002570"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117492","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117492"}}